The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease (HD)
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925001527 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|